Business
Embecta owns, and BD provides Embecta a license to use, intellectual property rights necessary to operate our business.
Embecta Corp.: Revenue declined 3.8% to $1.08B from $1.123B. Net income grew 21.8% to $95.4M from $78.3M. Free cash flow grew 816.6% to $182M from $19.9M. Operating margin expanded 756 bps to 22.41%. Embecta Corp.'s annual comparison also shows stock compensation grew faster than revenue; inventory grew faster than revenue.
The read at a glance✓ Audited against SEC data
- Growth — Revenue declined 3.8% to $1.08B from $1.123BWatch
- Profitability — Net income grew 21.8% to $95.4M from $78.3MOK
- Cash flow — Free cash flow grew 816.6% to $182M from $19.9MOK
- Margins — Operating margin expanded 756 bps to 22.41%OK
- Accounting — No overriding statistical warningNote
- Insiders — 0 purchases and 0 salesNote
Where the revenue comes from
Fiscal 2025, as Embecta Corp. reports it. History and quarterly detail are in the app.
- Pen Needles$784.1M
- Safety$137.8M
- Syringes$124.6M
- Contract Manufacturing$19.9M
- Other$14.0M
Leadership changes
From Embecta Corp.'s own filings, the day they're filed.
- David A. Albritton · member of the board of directors · departureeff. 2025-11-17
- Anthony Roth · President · appointmenteff. 2024-12-02
- Jake Elguicze · Chief Financial Officer · appointmenteff. 2024-08-12
Latest filings
- 8-K · Company announcement2026-08-07
- 10-Q · Quarterly report2026-08-07
- 8-K · Company announcement2026-05-15
- 10-Q · Quarterly report2026-05-05
- 8-K · Company announcement2026-05-05
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Embecta Corp., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.